Copyright Reports & Markets. All rights reserved.

Covid-19 Impact on Neurodegenerative Drugs Market, Global Research Reports 2020-2021

Request for Sample of this report
Buy now
  • 1.1 Research Scope
  • 1.2 Market Segmentation
  • 1.3 Research Objectives
  • 1.4 Research Methodology
    • 1.4.1 Research Process
    • 1.4.2 Data Triangulation
    • 1.4.3 Research Approach
    • 1.4.4 Base Year
  • 1.5 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth
    • 1.5.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
    • 1.5.2 Covid-19 Impact: Commodity Prices Indices
    • 1.5.3 Covid-19 Impact: Global Major Government Policy
  • 1.6 The Covid-19 Impact on Neurodegenerative Drugs Industry
  • 1.7 COVID-19 Impact: Neurodegenerative Drugs Market Trends

    • 2 Global Neurodegenerative Drugs Quarterly Market Size Analysis

    • 2.1 Neurodegenerative Drugs Business Impact Assessment - COVID-19
      • 2.1.1 Global Neurodegenerative Drugs Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
      • 2.1.2 Global Neurodegenerative Drugs Price, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
    • 2.2 Global Neurodegenerative Drugs Quarterly Market Size 2020-2021
    • 2.3 COVID-19-Driven Market Dynamics and Factor Analysis
      • 2.3.1 Drivers
      • 2.3.2 Restraints
      • 2.3.3 Opportunities
      • 2.3.4 Challenges

    3 Quarterly Competitive Assessment, 2020

    • 3.1 Global Neurodegenerative Drugs Quarterly Market Size by Manufacturers, 2019 VS 2020
    • 3.2 Global Neurodegenerative Drugs Factory Price by Manufacturers
    • 3.3 Location of Key Manufacturers Neurodegenerative Drugs Manufacturing Factories and Area Served
    • 3.4 Date of Key Manufacturers Enter into Neurodegenerative Drugs Market
    • 3.5 Key Manufacturers Neurodegenerative Drugs Product Offered
    • 3.6 Mergers & Acquisitions, Expansion Plans

    4 Impact of Covid-19 on Neurodegenerative Drugs Segments, By Type

    • 4.1 Introduction
      • 1.4.1 NMDA
      • 1.4.2 SSRIs
      • 1.4.3 Dopamine Inhibitors
    • 4.2 By Type, Global Neurodegenerative Drugs Market Size, 2019-2021
      • 4.2.1 By Type, Global Neurodegenerative Drugs Market Size by Type, 2020-2021
      • 4.2.2 By Type, Global Neurodegenerative Drugs Price, 2020-2021

    5 Impact of Covid-19 on Neurodegenerative Drugs Segments, By Application

    • 5.1 Overview
      • 5.5.1 Parkinson’s Disease
      • 5.5.2 Huntington Disease
      • 5.5.3 Amyotrophic Lateral Sclerosis
      • 5.5.4 Alzheimer’s Disease
    • 5.2 By Application, Global Neurodegenerative Drugs Market Size, 2019-2021
      • 5.2.1 By Application, Global Neurodegenerative Drugs Market Size by Application, 2019-2021
      • 5.2.2 By Application, Global Neurodegenerative Drugs Price, 2020-2021

    6 Geographic Analysis

    • 6.1 Introduction
    • 6.2 North America
      • 6.2.1 Macroeconomic Indicators of US
      • 6.2.2 US
      • 6.2.3 Canada
    • 6.3 Europe
      • 6.3.1 Macroeconomic Indicators of Europe
      • 6.3.2 Germany
      • 6.3.3 France
      • 6.3.4 UK
      • 6.3.5 Italy
    • 6.4 Asia-Pacific
      • 6.4.1 Macroeconomic Indicators of Asia-Pacific
      • 6.4.2 China
      • 6.4.3 Japan
      • 6.4.4 South Korea
      • 6.4.5 India
      • 6.4.6 ASEAN
    • 6.5 Rest of World
      • 6.5.1 Latin America
      • 6.5.2 Middle East and Africa

    7 Company Profiles

    • 7.1 Novartis
      • 7.1.1 Novartis Business Overview
      • 7.1.2 Novartis Neurodegenerative Drugs Quarterly Production and Revenue, 2020
      • 7.1.3 Novartis Neurodegenerative Drugs Product Introduction
      • 7.1.4 Novartis Response to COVID-19 and Related Developments
    • 7.2 Pfizer
      • 7.2.1 Pfizer Business Overview
      • 7.2.2 Pfizer Neurodegenerative Drugs Quarterly Production and Revenue, 2020
      • 7.2.3 Pfizer Neurodegenerative Drugs Product Introduction
      • 7.2.4 Pfizer Response to COVID-19 and Related Developments
    • 7.3 Merck Serono
      • 7.3.1 Merck Serono Business Overview
      • 7.3.2 Merck Serono Neurodegenerative Drugs Quarterly Production and Revenue, 2020
      • 7.3.3 Merck Serono Neurodegenerative Drugs Product Introduction
      • 7.3.4 Merck Serono Response to COVID-19 and Related Developments
    • 7.4 Biogen Idec
      • 7.4.1 Biogen Idec Business Overview
      • 7.4.2 Biogen Idec Neurodegenerative Drugs Quarterly Production and Revenue, 2020
      • 7.4.3 Biogen Idec Neurodegenerative Drugs Product Introduction
      • 7.4.4 Biogen Idec Response to COVID-19 and Related Developments
    • 7.5 TEVA
      • 7.5.1 TEVA Business Overview
      • 7.5.2 TEVA Neurodegenerative Drugs Quarterly Production and Revenue, 2020
      • 7.5.3 TEVA Neurodegenerative Drugs Product Introduction
      • 7.5.4 TEVA Response to COVID-19 and Related Developments
    • 7.6 UCB
      • 7.6.1 UCB Business Overview
      • 7.6.2 UCB Neurodegenerative Drugs Quarterly Production and Revenue, 2020
      • 7.6.3 UCB Neurodegenerative Drugs Product Introduction
      • 7.6.4 UCB Response to COVID-19 and Related Developments
    • 7.7 Boehringer Ingelheim
      • 7.7.1 Boehringer Ingelheim Business Overview
      • 7.7.2 Boehringer Ingelheim Neurodegenerative Drugs Quarterly Production and Revenue, 2020
      • 7.7.3 Boehringer Ingelheim Neurodegenerative Drugs Product Introduction
      • 7.7.4 Boehringer Ingelheim Response to COVID-19 and Related Developments
    • 7.8 Sanofi
      • 7.8.1 Sanofi Business Overview
      • 7.8.2 Sanofi Neurodegenerative Drugs Quarterly Production and Revenue, 2020
      • 7.8.3 Sanofi Neurodegenerative Drugs Product Introduction
      • 7.8.4 Sanofi Response to COVID-19 and Related Developments
    • 7.9 GlaxoSmithKline
      • 7.9.1 GlaxoSmithKline Business Overview
      • 7.9.2 GlaxoSmithKline Neurodegenerative Drugs Quarterly Production and Revenue, 2020
      • 7.9.3 GlaxoSmithKline Neurodegenerative Drugs Product Introduction
      • 7.9.4 GlaxoSmithKline Response to COVID-19 and Related Developments

    8 Supply Chain and Sales Channels Analysis

    • 8.1 Neurodegenerative Drugs Supply Chain Analysis
      • 8.1.1 Neurodegenerative Drugs Supply Chain Analysis
      • 8.1.2 Covid-19 Impact on Neurodegenerative Drugs Supply Chain
    • 8.2 Distribution Channels Analysis
      • 8.2.1 Neurodegenerative Drugs Distribution Channels
      • 8.2.2 Covid-19 Impact on Neurodegenerative Drugs Distribution Channels
      • 8.2.3 Neurodegenerative Drugs Distributors
    • 8.3 Neurodegenerative Drugs Customers

    9 Key Findings

      10 Appendix

      • 10.1 About Us

      This report covers market size and forecasts of Neurodegenerative Drugs, including the following market information:
      Global Neurodegenerative Drugs Market Size, 2019-2021, and 2020 (quarterly data), (US$ Million) & (MT)
      Global Neurodegenerative Drugs Market Size by Type and by Application, 2019-2021, and 2020 (quarterly data), (US$ Million) & (MT)
      Global Neurodegenerative Drugs Market Size by Region (and Key Countries), 2019-2021, and 2020 (quarterly data), (US$ Million) & (MT)
      Global Neurodegenerative Drugs Market Size by Company, 2019- 2020 (quarterly data), (US$ Million) & (MT)

      Key market players
      Major competitors identified in this market include Novartis, Pfizer, Merck Serono, Biogen Idec, TEVA, UCB, Boehringer Ingelheim, Sanofi, GlaxoSmithKline, etc.

      Based on the Region:
      Asia-Pacific (China, Japan, South Korea, India and ASEAN)
      North America (US and Canada)
      Europe (Germany, France, UK and Italy)
      Rest of World (Latin America, Middle East & Africa)

      Based on the Type:
      NMDA
      SSRIs
      Dopamine Inhibitors

      Based on the Application:
      Parkinson’s Disease
      Huntington Disease
      Amyotrophic Lateral Sclerosis
      Alzheimer’s Disease

      Buy now